Skip to content
Screener

Sutro Biopharma STRO Q3 2026 earnings

Reported November 12, 2026 · After market close

Revenue$9.1MMiss by $5.0M
EPS-$1.90Miss by $0.26
Revenue estimate$14.1M
EPS estimate-$1.64
“Over the past year, we have delivered on our commitment to advance our next-generation ADCs with two programs, STRO-004 and STRO-006, entering the clinic in less than a year, and our dual-payload ADC, STRO-227, expected to follow in early 2027. Early data from STRO-004 give us confidence in its potential to deliver meaningful clinical benefit with our proprietary ADC platform. In addition, our collaboration partner Astellas has initiated patient dosing with a second dual-payload immunostimulatory ADC, further highlighting our strong execution and ability to deliver differentiated, novel dual-payload ADCs. Together these advances reflect our proficiency in translating platform innovation into a growing pipeline of therapies designed to improve patient outcomes and create long-term value.”
Jane Chung

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$9.1M-6.1%
Operating income-$22.0M+54.7%
Net income-$31.5M+44.6%
EPS (diluted)-$1.90-184%

Balance sheet

See full
Cash & equivalents$46.9M-28.9%
Total debt$9.7M-45.1%
Total equity-$132.5M-51.9%
Total assets$176.6M-15.7%

Cash flow

See full
Operating cash flow-$22.5M+41.2%
Free cash flow-$22.4M+41.5%

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$175.93M+156%
Enterprise value$138.78M+582%
P/S3.9×+3.3×

Profitability

See full
Operating margin-265%+275pp
Net margin-344.2%+724pp
FCF margin-287.2%+164pp

Returns & leverage

See full
Current ratio2.9×+0.4×

Segments

By product

See full
Ongoing Performance Related To Unsatisfied Performance Obligations$6.1M+1.9%
Materials Supply$1.8M-27.1%
Financing Component On Unearned Revenue$844.0K+30.7%
Research And Development Services$366.0K-30.2%

FAQ

When did Sutro Biopharma report Q3 2026 earnings?
Sutro Biopharma (STRO) reported Q3 2026 earnings on November 12, 2026 after market close.
What were Sutro Biopharma's Q3 2026 revenue and EPS?
Sutro Biopharma reported revenue of $9.1M and eps of $-1.90 for Q3 2026.
Did Sutro Biopharma beat estimates in Q3 2026?
Revenue missed the consensus estimate of $14.1M by $5.0M. EPS missed the consensus estimate of $-1.64 by $0.26.
How did Sutro Biopharma's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 6.1% from $9.7M a year earlier and eps grew 71.6% from $-6.70.
Where can I find Sutro Biopharma's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-458641) and the 10-Q periodic report (0001193125-26-458680) directly on SEC EDGAR. The filing index links above go to sec.gov.